S3 Ep17: Talking KRAS-Targeted Therapy in NSCLC With Dr. Drilon
S3 Ep16: Research Reflections: Weinberg Weighs in on Thought-Provoking Data in CRC
S3 Ep15: FDA Approval Insights: Olaparib in HRR-Mutant mCRPC
S3 Ep14: Marvels in Medicine: Vokes’s Venture to Bring Combined Modality Care to Patients With Cancer
S3 Ep13: Integrating Nutrition Into the Continuum of Cancer Care
S3 Ep12: FDA Approval Insights: Nivolumab/Ipilimumab in Advanced NSCLC
S3 Ep11: Marvels in Medicine: Dr. Gradishar on the Personal Pursuit of Precision Medicine in Breast Cancer
S3 Ep10: Research Reflections: Hamid Homes in on Key Efforts Made in Melanoma
S3 Ep9: Reviewing the Risk-Benefit Ratio of Adjuvant and Neoadjuvant Approaches in Melanoma
S3 Ep8: Chowdhary Covers Risk-Reducing Strategies and Recommendations During the COVID-19 Era
S3 Ep7: Marvels in Medicine: Dr. Karlan on Breaking Down Gender Barriers in Gynecologic Oncology
S3 Ep6: Dr. Burris and Dr. Graff Talk COVID-19 and Cancer Care, Telemedicine, and ASCO Initiatives
S3 Ep5: FDA Approval Insights: Subcutaneous Daratumumab in Multiple Myeloma
S3 Ep4: McGregor Details GU Treatment Guidelines During COVID-19 Pandemic
S3 Ep3: FDA Approval Insights: Olaparib/Bevacizumab in Advanced Ovarian Cancer
S3 Ep2: Talking Tumors: Exploring Management Strategies in Multiple Myeloma
S3 Ep1: Making Headway in GI Malignancies in Miami
S2 Ep50: The Uromigos Unveil Updates and Insights on the Impact of COVID-19 on GU Cancers
S2 Ep49: Marvels in Medicine: Gabriel Hortobagyi on Challenging Historical Dogmas in Breast Cancer
S2 Ep48: FDA Approval Insights: Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
S2 Ep47: Observing Optimal Treatment Strategies in Ovarian Cancer in Ohio
S2 Ep46: Talking Tumors: Treating With Immunotherapy and Targeted Therapy in Lung Cancer
S2 Ep45: Navigating Newfound GU Treatment Considerations in the Context of COVID-19
S2 Ep44: Physician and Patient Perspectives on Diagnosis and Treatment in Essential Thrombocythemia
S2 Ep43: Homing in on Clinical Advances in Hematologic Malignancies in Chicago
S2 Ep42: Gaining Ground in Genitourinary Malignancies in Nashville
S2 Ep41: Talking HER2-Targeted Therapy With Dr. Ajani
S2 Ep40: Talking HER2-Targeted Therapy With Dr. Chau
S2 Ep39: Talking HER2-Targeted Therapy With Dr. Marshall
S2 Ep38: Talking HER2-Targeted Therapy With Dr. Corcoran
S2 Ep37: Dr. Marshall Calls for Continued Discourse on Physician Burnout in Oncology
S2 Ep36: Collaborative Efforts Lead to the Launch of the COVID-19 and Cancer Consortium Registry
S2 Ep35: FLASCO Faculty Flesh Out Case Studies in GI Cancers
S2 Ep34: Spotlighting New Standards of Care in Lung Cancer in Summit
S2 Ep33: Maurie Markman, MD: Confronting the Complexities of Care in Gynecologic Cancers
S2 Ep32: Navigating NGS and Novel Therapies in GI Malignancies in New York
S2 Ep31: Talking Tumors: Turning to Liquid Biopsies and Immunotherapy in Lung Cancer
S2 Ep30: Unpacking IO Innovations in Lung Cancer in Pittsburgh
S2 Ep29: Jeffrey Weber, MD, PhD: Charting New Territories in Melanoma
S2 Ep28: Analyzing the Application of Precision Medicine in Austin
S2 Ep27: Talking Tumors: Contemplating Clinical Conundrums in Lung Cancer
S2 Ep26: Pondering Progress Made in GU Cancers in Phoenix
S2 Ep25: Collaboration Saves Lives: Managing irAEs is a "Dynamic Discussion"
S2 Ep24: Airing Treatment Advances in Breast Cancer in New York
S2 Ep23: Stephanie Graff, MD: Information Is Power for Patients With Breast Cancer
S2 Ep22: Outlining Advances Made in Ovarian Cancer in Oklahoma City
S2 Ep21: Talking Tumors: Weill Cornell Medicine Experts Walk Through Challenging Breast Cancer Cases
S2 Ep20: Highlighting Progress Made in Hematologic Malignancies in Philly
S2 Ep19: Checking Out Emerging Approaches in Lung Cancer Treatment in Chicago
S2 Ep18: Tanios Bekaii-Saab, MD: Not Just Seeing the Light, But Getting Out of the Tunnel
next page